Citations

Clear

1031 citation(s) found for "Clark, AS".

In patients with ASCVD and elevated LDL-C with maximal statin therapy, inclisiran reduced LDL-C levels at 18 months
Clark, Jennifer , Montori, Víctor M.

Mayo Clinic

Annals of Internal Medicine | August 17, 2020 | Volume: 173 | Issue: 4 | Pages: JC18

10.7326/acpj202008180-018 | PMID 32805173 Get It

Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single‐center analysis
Owoyemi, Itunu , Vaughan, Lisa E. , Costello, Collin M. , Thongprayoon, Charat , Markovic, Svetomir N. , Herrmann, Joerg , Otley, Clark C. , Taner, Timuçin , Mangold, Aaron R. , Leung, Nelson , Kukla, Aleksandra , Herrmann, Sandra M , Kukla, Aleksandra , Mangold, A R , Leung, Nelson , Thongprayoon, Charat , Markovic, Svetomir , Costello, Collin M , Herrmann, Sandra M.

Mayo Clinic

Cancer | August 12, 2020 | Volume: 126 | Issue: 21 | Pages: 4780-4787

10.1002/cncr.33134 | PMID 32786022 Get It

Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but to the authors' knowledge, limited data exist regarding the safety and efficacy of these agents in transplant recipients. Herein, the authors have reported their experience with 17 patients who were treated with ICIs for metastatic malignancies after undergoing solid organ transplantation. Methods Data were abstracted for solid organ transplant recipients who received ICIs for the treatment of malignancy between January 1, 2016, and September 30, 2019. The authors identified 7 kidney, 8 liver, and 2 heart transplant recipients. Outcomes of interest were adverse drug reactions, cancer progression, and patient survival. Results The most common malignancies treated with ICIs were metastatic squamous cell carcinoma (5 patients; 29%) and hepatocellular carcinoma (5 patients; 29%), which were noted exclusively among liver transplant recipients. The median duration on ICIs was 1.7 months (interquartile range, 0.4‐7.6 months). Five patients (29%) developed adverse reactions, including 4 patients (24%) with immune‐related adverse events(irAEs), 3 patients (18%) with acute allograft rejections, 1 patient (6%) with autoimmune colitis, and 1 patient (6%) with ICI‐induced cardiotoxicity (the patient was a heart transplant recipient). The cumulative incidence of cancer progression was 50% and 69%, respectively, at 6 months and 12 months. Eleven patients (65%) died over the median follow‐up period of 4.6 months (interquartile range, 1.5‐13.2 months) from the time of ICI initiation, with cancer progression being the most common cause of death. Conclusions ICIs can be used as individualized therapy in selected patients who have undergone solid organ transplantation but more studies are needed to determine how best to use these agents to improve outcomes further.
Building the vertebrate codex using the gene breaking protein trap library
Ichino, Noriko , Serres, MaKayla R., Urban, Rhianna , Urban, Mark D. , Treichel, Anthony J. , Schaefbauer, Kyle, Tallant, Lauren , Varshney, Gaurav K. , Skuster, Kimberly J., McNulty, Melissa S. , Daby, Camden L. , Wáng, Ying , Liao, Hsin‐Kai, El‐Rass, Suzan , Liu, Weibin , Anderson, Jennifer L. , Wishman, Mark , Sabharwal, Ankit , Schimmenti, Lisa A. , Sivasubbu, Sridhar , Balciunas, Darius , Hammerschmidt, Matthias , Farber, Steven , Wen, Xiao‐Yan , McGrail, Maura , Burgess, Shawn M. , Ekker, Stephen C. , Urban, Rhianna M , Schaefbauer, Kyle J., Tallant, Lauren E., Ding, Yonghe , Wishman, Mark D, Sabharwal, Ankit , Balciunas, Darius , Hammerschmidt, Matthias , Farber, Steven Arthur , Lin, Xueying , McGrail, Maura , Essner, Jeffrey , Burgess, Shawn M , Clark, Karl J , Ekker, Stephen C , Wen, Xiao-Yan , Schimmenti, Lisa A , Treichel, Anthony J , Ichino, Noriko , Xu, Xiaolei , Essner, Jeffrey J. , Clark, Karl J.

Mayo Clinic

eLife | August 11, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.54572 | PMID 32779569 Get It

One key bottleneck in understanding the human genome is the relative under-characterization of 90% of protein coding regions. We report a collection of 1200 transgenic zebrafish strains made with the gene-break transposon (GBT) protein trap to simultaneously report and reversibly knockdown the tagged genes. Protein trap-associated mRFP expression shows previously undocumented expression of 35% and 90% of cloned genes at 2 and 4 days post-fertilization, respectively. Further, investigated alleles regularly show 99% gene-specific mRNA knockdown. Homozygous GBT animals in ryr1b , fras1 , tnnt2a , edar and hmcn1 phenocopied established mutants. 204 cloned lines trapped diverse proteins, including 64 orthologs of human disease-associated genes with 40 as potential new disease models. Severely reduced skeletal muscle Ca 2+ transients in GBT ryr1b homozygous animals validated the ability to explore molecular mechanisms of genetic diseases. This GBT system facilitates novel functional genome annotation towards understanding cellular and molecular underpinnings of vertebrate biology and human disease.
Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia
Utianski, Rene L. , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Clark, Heather M. , Duffy, Joseph R. , Botha, Hugo

Mayo Clinic

American Journal of Speech-Language Pathology | August 5, 2020 | Volume: 29 | Issue: 4 | Pages: 1976-1986

10.1044/2020_ajslp-20-00012 | PMID 32755493 Get It

Purpose Individuals with primary progressive apraxia of speech (AOS) have AOS in which disruptions in articulation and prosody predominate the speech pattern. Many develop aphasia and/or dysarthria later in the disease course. The aim of this study was to describe the communication limitations in these patients, as measured by (a) the patient via the Communicative Participation Item Bank (CPIB) and (b) the speech-language pathologist via the American Speech-Language-Hearing Association's (ASHA) Functional Communication Measures (FCMs) and an adapted motor speech disorder (MSD) severity rating. Method Speech and language evaluations were completed for 24 patients with progressive AOS ( n = 7 with isolated AOS; n = 17 with a combination of AOS and aphasia). Descriptive comparisons were utilized to evaluate differences in communication measures among patients with various combinations of MSDs and aphasia. Differences associated with phonetic predominant or prosodic predominant AOS were also examined. Across the entire cohort, correlations were calculated between the participation ratings and other clinical assessment measures. Results The CPIB reflected greater limitations for those with aphasia and AOS compared to isolated AOS, but was not notably different when dysarthria occurred with AOS ( n = 9/24). Across the cohort, there were statistically significant correlations between the CPIB and ASHA FCM–Motor Speech and Language Expression ratings and the MSD severity rating. The CPIB did not correlate with the ASHA FCM–Language Comprehension or other speech-language measures. Conclusions Patients with neurodegenerative AOS experience reduced participation in communication that is further exacerbated by co-occurring language deficits. The study suggests measures of severity cannot be assumed to correlate with measures of participation restrictions and offers a foundation for further research examining the day-to-day sequela of progressive speech and language disorders. Supplemental Material https://doi.org/10.23641/asha.12743252
Feasibility of a Behavioral Intervention to Reduce Psychological Distress in Mechanically Ventilated Patients
Tan, Yanni , Gajić, Ognjen, Schulte, Phillip J. , Clark, Matthew M. , Philbrick, Kemuel L. , Karnatovskaia, Lioudmila V. , Karnatovskaia, Lioudmila , Gajic, Ognjen

Mayo Clinic

International Journal of Clinical and Experimental Hypnosis | July 31, 2020 | Volume: 68 | Issue: 4 | Pages: 419-432

10.1080/00207144.2020.1795663 | PMID 32730136 Get It

Early Implant Failure of a 2-Level M6-Cervical Total Disc Replacement
Clark, Nicholas J. , Francois, Elvis L. , Freedman, Brett A. , Currier, Bradford L. , Currier, Bradford

Mayo Clinic

JBJS Case Connector | July 29, 2020 | Volume: 10 | Issue: 3 | Pages: e19.00644-e19.00644

10.2106/jbjs.cc.19.00644 | PMID 32773711 Get It

Case: We report a case of implant failure after primary 2-level M6-cervical disc replacement (M6-C; Spinal Kinetics) at C4-5 and C5-6. At revision surgery, a full-thickness tear was identified in the sheath of the C5-6 implant. Histology from periprosthetic tissue demonstrated polyethylene particles without acute inflammation. Tissue cultures were positive for Propionibacterium acnes , but ultrasonicate cultures were negative for both prostheses. An independent laboratory test confirmed mechanical failure of the C5-6 prosthesis. Conclusion: This is the first report of mechanical failure associated with wear-debris osteolysis after M6-C disc arthroplasty. Therefore, continued surveillance after CTDR is necessary.
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
Yee, Douglas , Symmans, W. Fraser , Albain, Kathy S. , Chen, Yunn-Yi, Krings, Gregor , Wei, Shi , Harada, Shuko , Datnow, Brian, Fadare, Oluwole , Klein, Molly, Chen, Beiyun, Adamson, Kathi, Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Magliocco, Anthony M., Feldman, Mike, Rendi, Mara H. , Sattar, Husain, Zeck, Jay , Ocal, Idris Tolgay, Tawfik, Ossama , LeBeau, Lauren, Sahoo, Sunati , Vinh, Tuyethoa N., Chien, A. Jo , Forero‐Torres, Andres , Stringer-Reasor, Erica , Ellis, Erin D. , Lu, Janice , Lang, Julie E. , Clark, Amy S. , Nanda, Rita , Northfelt, Donald W. , Khan, Qamar J. , Viscusi, Rebecca K., Euhus, David , Edmiston, Kirsten K., Kemmer, Kathleen, Park, John W., Liu, Minetta C. , Olopade, Olufunmilayo I. , Leyland‐Jones, Brian , Tripathy, Debasish , Moulder, Stacy L. , Schwab, Richard B. , Lo, Shelly S. , Beckwith, Heather , Haugen, Patricia, Veer, Laura J. van’t , Perlmutter, Jane , Melisko, Michelle , Wilson, Amy , Peterson, Garry , Buxton, Meredith , Paoloni, Melissa, Clennell, Julia L. , Hirst, Gillian L. , Singhrao, Ruby , Steeg, Katherine, Matthews, Jeffrey B. , Asare, Smita , Sanil, Ashish, Esserman, Laura J. , Berry, Donald A. , Tripathy, Debu , Ocal, Idris T, Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , DeMichele, Angela , Yau, Christina , Isaacs, Claudine , Chen, Yunn‐Yi , Krings, Gregor, Pambuccian, Stefan E. , Wallace, Anne M. , Pusztai, Lajos , Boughey, Judy C. , Elias, Anthony , Han, Hyo S , Chui, Stephen Y., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Asare, Adam L. , Matthews, Jeffrey B., Berry, Scott

Mayo Clinic

JAMA Oncology | July 23, 2020 | Volume: 6 | Issue: 9 | Pages: 1355

10.1001/jamaoncol.2020.2535 | PMID 32701140 Get It

National trends in prescription drug expenditures and projections for 2020
Tichy, Eric M. , Schumock, Glen T., Hoffman, James M. , Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Stubbings, JoAnn , Cuéllar, Sandra , Clark, John Spencer , Wiest, Michelle D., Matusiak, Linda M., Hunkler, Robert J., Vermeulen, Lee C.

Mayo Clinic

American Journal of Health-System Pharmacy | July 23, 2020 | Volume: 77 | Issue: 15 | Pages: 1213-1230

10.1093/ajhp/zxaa116 | PMID 32412055 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2020 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2020 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for specialty drugs, biosimilars, and diabetes medications. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2020 were based on a combination of quantitative analyses and expert opinion. Results In 2019, overall US pharmaceutical expenditures grew 5.4% compared to 2018, for a total of $507.9 billion. This increase was driven to similar degrees by prices, utilization, and new drugs. Adalimumab was the top drug in US expenditures in 2019, followed by apixaban and insulin glargine. Drug expenditures were $36.9 billion (a 1.5% increase from 2018) and $90.3 billion (an 11.8% increase from 2018) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals growth was driven by new products and price increases. Several new drugs that will likely influence spending are expected to be approved in 2020. Specialty and cancer drugs will continue to drive expenditures. Conclusion For 2020 we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 9.0% to 11.0% and 2.0% to 4.0%, respectively, compared to 2019. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Psychiatric Disturbance or Parkinsonism as a Presentation of CNS Lymphoma: Observational Retrospective Study and Review of Literature
Dube, Sophia, Mountjoy, Luke , Ertz-Archambault, Natalie , Porter, Alyx B. , Mrugała, Maciej M. , Porter, Alyx, Sharma, Akanksha

Mayo Clinic

American Journal of Clinical Oncology | July 21, 2020 | Volume: 43 | Issue: 10 | Pages: 727-733

10.1097/coc.0000000000000738 | PMID 32694297 Get It

Objective: To evaluate the incidence of and characterize the presentation of neuropsychiatric symptoms and/or Parkinsonism as a presentation of central nervous system lymphoma (CNSL) in either its primary CNSL form or when it spreads to the brain in systemic diffuse large B-cell lymphoma (secondary CNSL). Patients and Methods: With Institutional Review Board approval we identified patients who had been treated at Mayo Clinic from 1998 to 2018 and were recorded to have a combination of ICD 9/10 codes for CNSL and various psychiatric diagnoses. Results: A total of 20 of the 232 patients (9%) were noted to have neuropsychiatric symptoms preceding diagnosis. The average age at diagnosis was 62, with even split for sex. The majority (85%) of patients had primary CNSL. The average duration of symptoms before the diagnosis was 4.8 months. Confusion (80%), depression (40%), apathy (30%), anxiety (30%), and agitation (30%) were the most common symptoms identified. The majority (65%) of patients had subcortical lesions followed by the frontal lobe (50%). Parkinsonism was identified in 5 of the 20 patients with 4 demonstrating resolution of symptoms with treatment of the lymphoma. Conclusions: Neuropsychiatric symptoms are a rare but notable symptom before the presentation of CNSL. There is an increasing awareness of neurological illness presenting as pure psychiatric disturbance, prompting the need to exclude organic and treatable diseases, particularly in elderly patients. Acknowledgment and diagnosis are important for an appropriate management as there is a significant impact on patient and caregiver quality of life.
Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma
Abraham, Roshini S. , Clark, Raynell, Bryant, Sandra C. , Lymp, James, Larson, Timothy , Kyle, Robert A. , Katzmann, Jerry A.

Mayo Clinic

Clinical Chemistry | July 17, 2020 | Volume: 48 | Issue: 4 | Pages: 655-657

10.1093/clinchem/48.4.655 Get It